Targeted NGS Profiling for Lung, Breast & Colorectal Cancers from Tissue and Liquid Biopsy
The IVDNGS™ Biopsy & Circulating Tumor Panel is a high-sensitivity, Next-Generation Sequencing (NGS)-based diagnostic assay developed to detect actionable mutations in lung, breast, and colorectal cancers. Designed for both tissue biopsy (FFPE) and liquid biopsy (cfDNA) samples, this panel enables minimally invasive tumor profiling, supporting early detection, monitoring, and personalized treatment decisions.
This assay targets clinically relevant genes involved in tumor growth, drug resistance, and metastasis, offering oncologists deep genomic insights for guiding targeted therapies and immunotherapies.
Covers high-priority cancer genes for lung, breast, and colorectal cancers
Detects SNVs, indels, CNVs, and gene fusions
Optimized for low-input cfDNA and FFPE tissue samples
High analytical sensitivity ideal for liquid biopsy applications
Supports real-time monitoring of treatment response & resistance
ISO 13485-compliant and IVD-ready assay
Non-small cell lung cancer (NSCLC) – EGFR, ALK, ROS1, KRAS
Breast cancer – BRCA1/2, PIK3CA, HER2
Colorectal cancer – KRAS, NRAS, BRAF, APC, TP53
Liquid biopsy for minimal residual disease (MRD) monitoring
Tissue biopsy for mutation-driven therapy decisions
| Step | Details |
|---|---|
| Sample Type | Plasma (cfDNA), FFPE tissue |
| DNA Input Requirement | ≥10 ng |
| Turnaround Time | 5–7 working days |
| Data Output | Annotated VCF, clinical interpretation report |
| Compatible Platforms | Illumina®, Ion Torrent™ |
Copyright © 2025 https://probgenbiotech.com/ All Rights Reserved.